Galapagos NV (NASDAQ:GLPG) Given Average Rating of "Reduce" by Brokerages

Shares of Galapagos NV (NASDAQ:GLPG - Get Free Report) have received an average rating of "Reduce" from the eight analysts that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $25.33.

A number of analysts have recently issued reports on GLPG shares. Wall Street Zen cut shares of Galapagos from a "hold" rating to a "sell" rating in a research note on Friday, April 25th. Barclays restated an "underweight" rating on shares of Galapagos in a research note on Thursday, January 23rd. Finally, Morgan Stanley cut shares of Galapagos from an "equal weight" rating to an "underweight" rating and cut their target price for the stock from $31.00 to $22.00 in a research note on Friday, February 14th.

Galapagos Stock Performance

GLPG stock traded down $0.05 during trading hours on Friday, reaching $28.73. The stock had a trading volume of 210,690 shares, compared to its average volume of 239,605. The stock has a 50-day simple moving average of $25.71 and a 200 day simple moving average of $25.94. Galapagos has a fifty-two week low of $22.36 and a fifty-two week high of $31.23.

Galapagos (NASDAQ:GLPG - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($2.24). The firm had revenue of $97.33 million for the quarter, compared to the consensus estimate of $72.22 million. As a group, equities analysts predict that Galapagos will post -1.6 EPS for the current year.

Hedge Funds Weigh In On Galapagos

A number of hedge funds have recently bought and sold shares of GLPG. R Squared Ltd bought a new position in Galapagos during the fourth quarter worth about $26,000. Wealthquest Corp bought a new position in Galapagos during the first quarter worth about $74,000. BNP Paribas Financial Markets increased its position in Galapagos by 45.9% during the fourth quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock worth $247,000 after acquiring an additional 2,824 shares during the period. GAMMA Investing LLC increased its position in Galapagos by 354.5% during the first quarter. GAMMA Investing LLC now owns 10,148 shares of the biotechnology company's stock worth $255,000 after acquiring an additional 7,915 shares during the period. Finally, QRG Capital Management Inc. increased its holdings in Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after buying an additional 1,866 shares during the period. 32.46% of the stock is owned by institutional investors.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.